Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells

Cell Transplantation

Volumn 7, Issue 1, 1998, Pages 1-9

  Peshwa, Madhusudan V ^a   Benike, Claudia ^b   Dupuis, Marc ^b   Kundu, Smriti K ^b   Engleman, Edgar G ^b   Merigan, Thomas C ^b   Van Schooten, Wim C A ^a  

^a Activated Cell Therapy   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic; Cytotoxic T lymphocyte (CTL); Dendritic cell; HIV; Immunotherapy

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; ANTIGEN PRESENTING CELL; ARTICLE; BREAST CANCER; CELL MEDIATED CYTOTOXICITY; CELL TRANSPLANTATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; DENDRITIC CELL; FLOW CYTOMETRY; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSPLANTATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; GENE PRODUCTS, TAX; HIV INFECTIONS; HLA-A ANTIGENS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOTHERAPY; ISOANTIGENS; LYMPHOMA, B-CELL; OLIGOPEPTIDES; TRANSPLANTATION, HOMOLOGOUS;

EID: 0031893668     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0963-6897(97)00004-3     Document Type: Article

References (25)

1. Borrow, P.; Evans, C.F.; Oldstone, M.B.A. Virus-induced immunosuppression: Immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J. Virol. 69:1059-1070; 1995.
2. Chehimi, J.; Prakash, K.; Shanmugam, V.; Jackson, S.J.; Bandyopadhyay, S.; Starr, S.E. In-vitro infection of peripheral blood dendritic cells with human immunodeficiency virus-1 causes impairment of a accessory functions. In: Kamperdijk, T., ed. Dendritic cells in fundamental and clinical immunology. New York: Plenum Press: 1993:521-526.
3. Dupuis, M.; Peshwa, M.V.; Benike, C.; Kundu, S.K.; Engleman, E.G.; van Schooten, W.C.A.; Merigan, T.C. Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1-infected and uninfected individuals. AIDS Res. Hum. Retrovir. 13:33-39; 1997.
4. Eales, L.-J.; Farrant, J.; Helbert, M.; Pinching, A.J. Peripheral blood dendritic cells in persons with AIDS and AIDS related complex: Loss of high intensity class II antigen expression and function. Clin. Exp. Immunol. 71:423-427; 1988.
5. Elovaara, I.; Koenig, S.; Brewah, A.Y.; Woods, R.M.; Lehky, T.S.J. High human T cell lymphotropic virus type I (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1 associated neurological disease. J. Exp. Med. 177:1567-1573; 1993.
6. Gabrilovich, D.I.; Kavanaugh, D.; Corak, J.; Nadaf-Rahrov, S.; Cunningham, T.; Carbone, D.P. Defective function of dendritic cells in patients with breast cancer can be overcome by generation of these cells from precursors. A new approach to cancer immunotherapy. Proc. Am. Soc. Clin. Oncol. March 15; 1996.
7. Grabbe, S.; Beissert, S.; Schwarz, T.; Granstein, R.D. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy? Immunol. Today 16:117-121; 1995.
8. Guery, J.-C.; Adorini, L. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. J. Immunol. 154:536-544; 1995.
9. Hsu, F.J.; Benike, C.; Fagnoni, F.; Liles, T.M.; Czerwinski, D.; Taidi, B.; Engleman, E.G.; Levy, R. Vaccination of patients with B cell lymphoma using autologous antigen pulsed dendritic cells. Nat Med. 2:52-58; 1996.
10. Hu, X.; Chakraborty, N.G.; Sporn, J.R.; Kurtzman, S.H.; Ergin, M.T.; Mukherji, B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 56: 2479-2483; 1996.
11. Inaba, K.; Metlay, J.P.; Crowley, M.T.; Steinman, R.M. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific MHC-restricted T cells in situ. J. Exp. Med. 172:631-640; 1990.
12. + cytotoxic T lymphocytes by dendritic cells. J. Exp. Med. 166:182-194; 1987.
13. Kannagi, M.; Shida, H.; Igarashi, H.; Kuruma, K.; Murai, H.; Aono, Y.; Maruyama, I.; Osame, M.; Hattori, T.; Inoko, H. Target epitope in the Tax protein of human T-cell leukemia virus type I recognized by class I major histocompatability complex-restricted cytotoxic T cells. J. Virol. 66:2928-2933; 1992.
14. Knight, S.C.; Macatonia, S.E.; Cruickshank, K.; Rudge, P.; Patterson, S. Dendritic cells in HIV-1 and HTLV-1 infection. In: Kamperdijk, T., ed. Dendritic cells in fundamental and clinical immunology. New York: Plenum Press: 1993: 545-549.
15. Macatonia, S.E.; Lau, R.; Patterson, S.; Pinching, A.J.; Knight, S.C. Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. Immunology 71:38-45; 1990.
16. Macatonia, S.E.; Patterson, S.; Knight, S.C. Primary proliferative and cytoxic T-cell responses to HIV induced in vitro by human dendritic cells. Immunology 74:399-406; 1991.
17. Mayordomo, J.I.; Zorina, T.; Storkus, W.J.; Zitvogel, L.; Celluzi, C.; Falo, L.D.; Melief, C.J.; Ildstad, S.T.; Kast, W.M.; Deleo, A.B.; Lotze, M.T. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med. 1:1297-1302; 1995.
18. + CTLs from naive precursors. J. Immunol. 153:996-1003; 1994.
19. Mukherji, B.; Chakraborty, N.G.; Yamasaki, S.; Okino, T.; Yamase, H.; Sporn, J.R.; Kurtzman, S.K.; Ergin, M.T.; Ozols, J.; Meehan, J.; Mauri, F. Induction of antigenspecific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA 92:8078-8082; 1995.
20. Nair, S.; Babu, J.S.; Dunham, R.G.; Kanda, P.; Burke, R.L.; Rouse, B.T. Induction of primary, antiviral cytotoxic, and proliferation responses with antigens administered via dendritic cells. J. Virol. 67:4062-4069; 1993.
21. + cytotoxic T-lymphocytes for adoptive immunotherapy. Biotechnol. Bioeng. 50:529-540; 1996.
22. Rooney, C.M.; Smith, C.A.; Ng, C.Y.C.; Loftin, S.; Li, C.; Krance, R.A.; Brenner, M.K.; Heslop, H.E. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9-13; 1995.
23. Steinman, R.M.; Witmer-Pack, M.; Inaba, K. Dendritic cells: Antigen presentation, accessory function and clinical relevance. In: Kamperdijk, T., ed. Dendritic cells in fundamental and clinical immunology. New York: Plenum Press: 1993:1-9.
24. + cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int. Immunol. 5:849-857; 1993.
25. Walter, E.A.; Greenberg, P.D.; Gilbert, M.J.; Flinch, R.J.; Watanabe, K.S.; Thomas, E.D.; Riddell, S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038-1043; 1995.